Insmed To Issue $206M In Stock To Fund Inhaled Antibiotics
Biopharmaceutical company Insmed Inc. is set to issue an additional $206 million of common stock, hoping to bring in net proceeds of $194 million for the development of its inhaled antibiotic...To view the full article, register now.
Already a subscriber? Click here to view full article